Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib
Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations
Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC
Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings
Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis
How can we continue to improve outcomes for our patients with lung cancer?
Advances made in the treatment of advanced lung cancer are now being introduced at earlier stages of disease
Poziotinib does not meet the expectations to target insertion mutations in HER2 exon 20 in NSCLC
The tyrosine kinase inhibitor shows signs of efficacy in treatment-naïve NSCLC with HER2 exon 20 insertions, but its safety profile remains a limiting factor
Combining WEE1 inhibition with PD-L1 blockade shows promise in SCLC models
Blocking the tyrosine kinase cell-cycle progression regulator WEE1 may help to reinstate tumour immunogenicity and potentiate the effects of immune checkpoint inhibitors
Will finding the optimal dosing regimen be the key to unlocking the potential of ATR inhibitors?
Novel scheduling of RP-3500 mitigates haematological toxicity and may facilitate combination therapy but tumour types most likely to respond remain to be defined
The genomic, immunological and clinical characterisation of breast cancer – a work in progress
A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Sitravatinib shows signals of enhancing checkpoint inhibitor efficacy in NSCLC progressing on immunotherapy
Early-phase trials suggest that sitravatinib may reboot the tumour response to PD-1 inhibitors, but confirmation of efficacy is required and strategies are needed to adjust tolerability
Exploring targeted degradation of KRAS G12C with PROTACs
Developing therapies for cancers harbouring KRAS mutations has proven difficult but PROTACs, acting via targeted protein degradation, may help combat previously undruggable proteins